Market capitalization | $3.35m |
Enterprise Value | $-4.33m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | 0.34 |
P/B ratio (TTM) P/B ratio | 0.46 |
Revenue growth (TTM) Revenue growth | -100.00% |
Revenue (TTM) Revenue | $0.00 |
EBIT (operating result TTM) EBIT | $-14.77m |
Free Cash Flow (TTM) Free Cash Flow | $-12.56m |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
2 Analysts have issued a Palisade Bio Inc forecast:
2 Analysts have issued a Palisade Bio Inc forecast:
Sep '24 |
+/-
%
|
||
Revenue | - - |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | -15 -15 |
11%
11%
|
EBIT (Operating Income) EBIT | -15 -15 |
10%
10%
|
Net Profit | -14 -14 |
5%
5%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Palisade Bio, Inc. is a biopharmaceutical company, which engages in the development of oral therapies that help patients with acute and chronic gastrointestinal complications stemming from post-operative digestive enzyme damage. It offers LB1148, an oral formulation of a broad-spectrum serine protease inhibitor designed to neutralize the activity of potent digestive proteases released from the gut during surgery. The company is headquartered in Carlsbad, CA.
Head office | United States |
CEO | J. Finley |
Employees | 9 |
Founded | 2011 |
Website | www.palisadebio.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.